SEC Form 4 · accession 0001104659-19-013869
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott A Canute
Director
Period of report
Mar 5, 2019
Accepted (ET)
Mar 11, 2019 · 4:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $16.96 | Mar 5, 2019 | A | 79,818 | A | — | Mar 5, 2026 | Common Stock, par value $0.01 per share | 79,818 | 79,818 | D |
| Stock Option (right to buy)F1 | $16.35 | Mar 8, 2019 | A | 22,854 | A | — | Mar 8, 2026 | Common Stock, par value $0.01 per share | 22,854 | 22,854 | D |
Explanation of responses
- F1The reporting person was granted stock options pursuant to the Issuer's 2014 Long-Term Incentive Plan. The stock options vest in full upon the Issuer's receipt of approval from the U.S. Food and Drug Administration for the Issuer's Biologics License Application for sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease under the Prescription Drug User Fee Act.